Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer

Lung cancer remains the leading cause of cancer death throughout the world. Despite new chemotherapeutic, immunomodulating and molecularly targeted agents, patients with locally advanced or metastatic disease still have a poor prognosis. This trial looked to combine antiangiogenic therapy with a fir...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Med
Auteurs principaux: Laslett, Nicole F., Park, SuJung, Masters, Gregory A., Biggs, David D., Schneider, Charles J., Misleh, Jamal G., Suppiah, Kathir, Simpson, Pamela S., Grubbs, Stephen, Wozniak, Timothy F., Guarino, Michael
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2018
Sujets:
Clinical Cancer Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6051222/
https://ncbi.nlm.nih.gov/pubmed/29905018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1569
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires